Real-World Adherence and Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists Therapy in Type 2 Diabetes Mellitus Patients in the United States
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
Aim: To assess adherence and discontinuation of injectable glucagon-like peptide-1 receptor agonists (GLP-1 RA) at 12 and 24 months among adult type 2 diabetes mellitus (T2DM) patients in the United States initiating GLP-1 RA using the administrative claims-based database, Optum Clinformatics ® Data Mart 7.1. Methods: A retrospective study was conducted from 01/2009 to 12/2017. Patients were required to be continuously enrolled for 12 months prior to their first GLP-1 RA prescription. Proportion of days covered (PDC) from prescription claims ≥ 0.80 defined adherence. Discontinuation was defined as a ≥ 90-day gap from the last date of GLP-1 RA supply to the first date of subsequent prescription claim. Results: A total of 4791 T2DM patients had ≥ 1 and 3907 had ≥ 2 GLP-1 RA prescription claims. 50.9% and 47.4% of patients were adherent at 12 and 24 months, respectively. Adherence was significantly higher among patients on weekly vs daily doses (p< 0.001). Median time to discontinuation was 13 months. The discontinuation rate was 47.7% and 70.1% at 12 and 24 months, respectively, with differences at 24 months for age and dosing frequency (p< 0.001 for both). Conclusion: Over half of T2DM patients initiating GLP-1 RA were non-adherent and the majority (70.1%) discontinued therapy by 24 months. Reasons for non-adherence and discontinuation merit further research. Keywords: GLP-1 RA, adherence, discontinuation, United States
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“At the 12- and 24-month time points after the initiation of GLP-1 RA, the percentage of men who qualified as adherent exceeded that of women (adherence rate: 54.2% for men versus 48.4% for women at 12 months and 51.1% versus 44.6% at 24 months, respectively, p < 0.01). With regard to the same time intervals, males also presented with lower rates of discontinuation of treatment (p < 0.01) [90].”
From Sex Differences in Response to Treatment with Glucagon-like Peptide 1 Receptor Agonists: Opportunities for a Tailored Approach to Diabetes and Obesity Care (2022) · cites this paper as [90]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Roughly, 50% of persons with type 2 diabetes and 68% of those engaging in weight loss care who start a GLP-1RA are reported to discontinue treatment after 1 year.6,7”
From Discontinuing glucagon-like peptide-1 receptor agonists and body habitus: A systematic review and meta-analysis (2025) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Males had lower treatment interruption rates and higher adherence rates than females, according to a retrospective study that looked at GLP-1 RA adherence and interruption rates [90].”
From Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance (2024) · cites this paper as [90]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“High and widely varying rates of GLP-1 RA discontinuation at 1 year have been reported, ranging from 37% to 81%.20,21,22,23,24”
From Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity (2025) · cites this paper as [21]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In real-world settings, up to half of those who initiate treatment with a GLP-1 receptor agonist have discontinued treatment after one year.14, 15, 16, 17”
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 4×
“10 In the SUSTAIN6 trial, 22.6% of patients on semaglutide prematurely discontinued therapy during the 24-month trial period.”
InfluentialSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900 · cited 1×
“29 Yet, in this real-world study, 70.1% of patients who initiated GLP-1 RA therapy discontinued therapy within 24 months.”
InfluentialGrundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000625 · Cited by 6,185
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.11.003 · Cited by 2,691
Prevalence of and Trends in Diabetes Among Adults in the United States, 1988-2012
Menke, A., Casagrande, S., Geiss, L., & Cowie, C. C. (2015) · JAMA · doi:10.1001/jama.2015.10029 · Cited by 2,362
Einarson, T. R., Acs, A., Ludwig, C., & Panton, U. H. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0728-6 · Cited by 2,312
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetologia · doi:10.1007/s00125-018-4729-5 · Cited by 1,455
Ho, P. M., Rumsfeld, J. S., Masoudi, F. A., McClure, D. L., Plomondon, M. E., Steiner, J. F., & Magid, D. J. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.17.1836 · Cited by 1,135
Methods for evaluation of medication adherence and persistence using automated databases
Andrade, S. E., Kahler, K. H., Frech, F., & Chan, K. A. (2006) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1230 · Cited by 1,079
Cited by
Items 101–127 of 127
Gonzalez, J. S., Wen, H., BUTERA, N. M., Uschner, D., Krause-Steinrauf, H. J., Gramzinski, M. R., Wexler, D. J., Petrovitch, H., Hoogendoorn, C. J., Crespo-Ramos, G., et al. (2026) · Diabetes Care · doi:10.2337/dc25-2008 · Cited by 3
Loizidis, G., & Summer, R. S. (2026) · Clinical Rheumatology · doi:10.1007/s10067-026-08212-w · Cited by 1
Liu, M. R., Cheng, Z. F., Li, L., Cai, H., Liu, J., Liu, J., Zheng, Y., Wang, S., Zhao, J., Yang, W., et al. (2026) · Annals of Internal Medicine · doi:10.7326/annals-25-04623 · Cited by 1
Discontinuation of glucagon-like peptide-1 receptor agonists among US adults: A national survey
DiStefano, M. J., Zon, J., Olson, E. G., Levy, J. F., Anderson, G. F., & Alexander, G. C. (2026) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2026.32.8.903 · Cited by 3
Waataja, J. J., Ikramuddin, S., Gal, D., & Billington, C. J. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.1002713 · Cited by 1
Renda, S., & Freeman, J. S. (2024) · Postgraduate Medicine · doi:10.1080/00325481.2024.2328511 · Cited by 2
Tan, X., Brady, B. L., Xie, L., & Paprocki, Y. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01741-8
Park, S. J., Rosen, R. L., Muñoz‐Vergara, D., Manson, J. E., Yeh, G. Y., Wayne, P. M., & Sesso, H. D. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5363323
Chen, L. L., Ludin, A. F. M., Manaf, Z. A., Tohit, N. M., & Shahar, S. (2025) · World Journal of Diabetes · doi:10.4239/wjd.v16.i8.104371 · Cited by 1
Beverly, E. A., Prabu, A., Joseph, J. J., Einstadter, D., Fiegl, J., Love, T. E., Jenkins, K., Lorenz, A., Uddin, S. J., Konstan, M. W., et al. (2025) · Clinical Diabetes · doi:10.2337/cd25-0025
Basal insulin in the age of innovation: are diamonds still forever?
Koufakis, T., Patoulias, D., Popovic, D. S., & Tsimihodimos, V. (2025) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2025.2580629
A consensus statement from the European Society for Clinical Investigation
Carbone, F., Després, J., Ioannidis, J. P. A., Neeland, I. J., Garruti, G., Busetto, L., Liberale, L., Ministrini, S., Vilahur, G., Schindler, T. H., et al. (2025) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Pagidipati, N. J. (2026) · Elsevier eBooks · doi:10.1016/b978-0-323-87862-3.00027-6
Zheng, X., Huang, X., & Huang, Y. (2026) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2025.12.009
Medication adherence and persistence of newly initiated medications in older adults with diabetes
Dombrowski, S. K., An, J., Huang, X., Lewis, M. W., Hayduk, V. A., Neugebauer, R. S., O’Connor, P. J., Schmittdiel, J. A., Hooker, S. A., Karter, A. J., et al. (2026) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2026.103075
Yang, S.-I., Kim, S. W., Son, K., Lee, S., Kim, J.-G., Roh, J.-I., & Sung, Y. C. (2026) · Nature Communications · doi:10.1038/s41467-026-71080-0 · Cited by 1
Rathore, G., & Singh, R. P. (2026) · Journal of Biomaterials Science Polymer Edition · doi:10.1080/09205063.2026.2675316
Matsuo, Y., Okada, A., Sakamoto, T., & Yasunaga, H. (2026) · Journal of Evidence-Based Medicine · doi:10.1111/jebm.70164
Haidar, L., & Delaney, J. A. (2026) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000001059 · Cited by 1
Gomon, Y. М., Колбин, А. С., Spichakova, E. A., & Reznik, V. A. (2026) · Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice · doi:10.37489/2588-0519-gcp-0022
Association of Glucagon‐Like Peptide—1 Receptor Analogues and Laryngeal Symptoms in Obese Adults
Shah, P., Kayekjian, D., Nguyen, S. A., Meenan, K. D., & O’Rourke, A. K. (2026) · The Laryngoscope · doi:10.1002/lary.70808
Wang, T., & Shiyanbola, O. O. (2026) · Current Diabetes Reports · doi:10.1007/s11892-026-01639-0
Vintila, A.-M., Masi, S., Esposti, L. D., Dovizio, M., Magné, J., Nugnes, M., Veronesi, C., Wolf, J., & Savarese, G. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03765-3
WRIGHT, E. E., HUANG, E., & Bindal, A. (2026) · Diabetes Technology & Therapeutics · doi:10.1177/15209156261489904
González-González, M. A., Pedrosa-Naudín, M. A., Fernández‐Lázaro, D., Planelles, I. D., Alvarez, E., & Gutiérrez‐Abejón, E. (2026) · Pharmaceuticals · doi:10.3390/ph19101607
Oria, L., & Darkhabani, M. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71474
Piccini, S., Giuseppe, F., Panico, C., Emanuela, M., Franco, F., Mazziotti, G., Andrea, L., & Mirani, M. (2023) · Zenodo (CERN European Organization for Nuclear Research) · doi:10.5281/zenodo.7533471
Metadata
- Authors
- Weiss, T., Carr, R. D., Pal, S., Yang, L., Sawhney, B., Boggs, R., Rajpathak, S., & Iglay, K.
- Affiliations
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- MSD (UK) Limited (United Kingdom) (GB)
- Corresponding author
- Weiss, Tracey
- ORCID
- Venue
- Patient Preference and Adherence
- Publisher
- Informa UK Limited
- Published
- 2020-11
- Volume
- Volume 14
- Pages
- 2337-2345
- ISSN
- 1177-889X (ISSN-L)
- PMC
- PMC7708309
- OpenAlex
- W3109831190
- Cited by
- 126
- References
- 37
- Citations by year
- 2026: 34 · 2025: 39 · 2024: 28 · 2023: 13 · 2022: 7 · 2021: 5
- FWCI
- 4.90
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Patient Preference and Adherence (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Funders
- American Diabetes Association
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- GLP-1 receptor agonists, type 2 diabetes, medication adherence, treatment discontinuation, proportion of days covered, dosing frequency, real-world evidence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.